Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): A trial of the Eastern cooperative oncology group

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 99-105

  Liu, Glenn ^a   Chen, Yu Hui ^b   Dipaola, Robert ^c   Carducci, Michael ^d   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

2 20 2011; BMS 247550; Chemotherapy; Epothilone; Microtubule inhibitor; NCT00087139; Version date

Indexed keywords

IXABEPILONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; FATIGUE; HUMAN; ILEUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROSTATE CANCER; SENSORY NEUROPATHY; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CASTRATION; DISEASE-FREE SURVIVAL; EPOTHILONES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84862104381     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.01.009     Document Type: Article

References (26)

1. A.C. Society Cancer Facts and Figures. 2011 2011 American Cancer Society Atlanta, GA
2. W. Berry, S. Dakhil, M. Modiano Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer J Urol 168 2002 2439 2443 (Pubitemid 35402635)
3. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
4. T.M. Beer, W. Berry, E.M. Wersinger Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years Clin Prostate Cancer 2 2003 167 172 (Pubitemid 38044664)
5. T.M. Beer, W.C. Pierce, B.A. Lowe Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 2001 1273 1279 (Pubitemid 32994757)
6. G.F. Sullivan, P.S. Amenta, J.D. Villanueva The expression of drug resistance gene products during the progression of human prostate cancer Clin Cancer Res 4 1998 1393 1403 (Pubitemid 28265221)
7. D.M. Bradshaw, R.J. Arceci Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance J Clin Oncol 16 1998 3674 3690 (Pubitemid 28506783)
8. A.C. Mita, L.J. Denis, E.K. Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
9. J.S. de Bono, S. Oudard, M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
10. F.Y. Lee, R. Borzilleri, C.R. Fairchild BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 2001 1429 1437 (Pubitemid 32708699)
11. S.H. Zhuang, M. Agrawal, M. Edgerly A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days Cancer 103 2005 1932 1938 (Pubitemid 40563267)
12. J. Abraham, M. Agrawal, S. Bakke Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days J Clin Oncol 21 2003 1866 1873 (Pubitemid 46638601)
13. S.M. Gadgeel, A. Wozniak, R.R. Boinpally Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design Clin Cancer Res 11 2005 6233 6239 (Pubitemid 41262953)
14. C. Aghajanian, H.A. Burris 3rd, S. Jones Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas J Clin Oncol 25 2007 1082 1088 (Pubitemid 46596760)
15. S. Mani, H. McDaid, A. Hamilton Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors Clin Cancer Res 10 2004 1289 1298 (Pubitemid 38365219)
16. M. Hussain, C.M. Tangen, P.N. Lara Jr Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial; S0111 J Clin Oncol 23 2005 8724 8729 (Pubitemid 46211517)
17. J.E. Rosenberg, V.K. Weinberg, W.K. Kelly Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563 (Pubitemid 47106144)
18. O. Smaletz, M. Galsky, H.I. Scher Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration Ann Oncol 14 2003 1518 1524 (Pubitemid 37304607)
19. M.D. Galsky, E.J. Small, W.K. Oh Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer J Clin Oncol 23 2005 1439 1446
20. C. Trivedi, B. Redman, L.E. Flaherty Weekly 1-hour infusion of paclitaxel Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma Cancer 89 2000 431 436 (Pubitemid 30489894)
21. W. Berry, S. Dakhil, M.A. Gregurich Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 suppl 15 2001 8 15 (Pubitemid 32947546)
22. A. Awada, M.J. Piccart, S.F. Jones Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy Cancer Chemother Pharmacol 63 2009 417 425
23. G.J. Bubley, M. Carducci, W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467 (Pubitemid 29517916)
24. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
25. H.I. Scher, S. Halabi, I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
26. S.K. Syed, M. Beeram, C.H. Takimoto Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers J Clin Oncol 22 2004 2028